These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22716080)

  • 1. Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes.
    Sutherland JJ; Raymond JW; Stevens JL; Baker TK; Watson DE
    J Med Chem; 2012 Jul; 55(14):6455-66. PubMed ID: 22716080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving molecules using multi-objective optimization: applying to ADME/Tox.
    Ekins S; Honeycutt JD; Metz JT
    Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building predictive ADMET models for early decisions in drug discovery.
    Penzotti JE; Landrum GA; Putta S
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADMET--Fifth Annual SMi Conference.
    Comer JE
    IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward in silico structure-based ADMET prediction in drug discovery.
    Moroy G; Martiny VY; Vayer P; Villoutreix BO; Miteva MA
    Drug Discov Today; 2012 Jan; 17(1-2):44-55. PubMed ID: 22056716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 13. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
    Srinivas NR
    Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Physico-chemical profiling of centrally acting molecules for prediction of pharmacokinetic properties].
    Deák K
    Acta Pharm Hung; 2008; 78(3):110-20. PubMed ID: 18986088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive approaches to increase absorption of compounds during lead optimisation.
    Valko K; Butler J; Eddershaw P
    Expert Opin Drug Discov; 2013 Oct; 8(10):1225-38. PubMed ID: 23865945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in computational methods for the prediction of ADMET properties.
    Clark DE; Grootenhuis PD
    Curr Opin Drug Discov Devel; 2002 May; 5(3):382-90. PubMed ID: 12058613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development.
    Di L; Feng B; Goosen TC; Lai Y; Steyn SJ; Varma MV; Obach RS
    Drug Metab Dispos; 2013 Dec; 41(12):1975-93. PubMed ID: 24065860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond profiling: using ADMET models to guide decisions.
    Segall M; Champness E; Obrezanova O; Leeding C
    Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
    J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.